Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07940881
PHASE1

A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors

Sponsor: SystImmune Inc.

View on ClinicalTrials.gov

Summary

The objective of the study is to evaluate the safety and tolerability of SI-B037 in participants with locally advanced or metastatic solid tumors.

Official title: SI-B037-ST-101: A Multicenter, Open-Label, Phase 1/1b, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SI-B037 in Adult Patients With Advanced/Metastatic Solid Tumors That Are Refractory to Standard Therapies

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

400

Start Date

2026-08-24

Completion Date

2029-11

Last Updated

2026-11-17

Healthy Volunteers

No

Interventions

DRUG

SI-B037

SI-B037 will be administered by intravenous (IV) infusion on Day 1 every 3 weeks

Locations (1)

NEXT Oncology

Houston, Texas, United States